is part of the Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Supply Chain

Foster Partners with Aran Biomedical to Market Long-Term Implantable Polypropylene

Image: Foster Corp./Aran Biomedical ProTEX Med polypropylene resin
ProTEX Med polypropylene is offered as a custom synthesized, permanently implantable polypropylene product.
The permanently implantable polymer market is growing rapidly, according to Foster. Making Aran’s ProTEX Med polypropylene more widely available will help designers develop new products that enable novel treatments.

Foster Corp. has entered into a business relationship with Aran Biomedical, a supplier of biomaterial products for implantable medical devices located in Galway, Ireland. Foster will work with Aran to market its long-term implantable polypropylene, ProTEX Med. 

Through this new partnership, Foster will be able to offer its customers ProTEX Med polypropylene to meet long-term, permanent implantable needs, while Aran will support the product technically and with regulatory backing. Foster currently provides cleanroom compounding services to companies that require permanently implantable materials with added functionality, such as bioresorbable polymers, PEEK, sulfones, and other thermoplastics. 

“We are well connected to companies that use this type of material,” said Larry Johnson, Vice President, Business Development, for Foster. “We have a great deal of experience working with customers that need implantable polymers through our unique ability to compound and find solutions. We have found a great partner in Aran, which wants to augment its marketing efforts for ProTEX Med PP by working with Foster to expand its market reach.”

Niall Rooney, Director of Business Development for Aran, commented: “ProTEX Med polypropylene is specifically offered as a custom synthesized, permanently implantable polypropylene product. Support for the product includes access to FDA Master File reference data, certification to technical specifications such as ISO 10993-5 (cytotoxicity  in vitro methods), as well as suitability to long-term clinical implantation supported by data from derived FDA 510(k) cleared surgical mesh.”

“The permanently implantable polymer market is growing rapidly and continuously needs new products and technologies that enable novel treatments,” said Johnson. “The expanded presence of Aran’s ProTEX Med polypropylene in the marketplace will provide numerous benefits for patients worldwide.”

Hide comments
account-default-image

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish